A 2025 Science Advances mouse study found a more brain-dependent metformin mechanism than the usual liver-gut framing suggests: low-dose metformin lost its glucose-lowering effect when brain Rap1 signaling could not be reduced, and 36 of 47 ventromedial-hypothalamus SF1 neurons responded directly to metformin.1 Research Highlights Low-dose metformin needed brain Rap1: Control mice lowered glucose after …
Patients with schizophrenia have substantially elevated dementia risk compared to the general population — roughly 2-3 times the age-adjusted rate — but the specific drivers within the schizophrenia population have been less well characterized. A 2026 case-control study by Ho et al. used population-based data to identify which factors specifically elevate dementia risk among schizophrenia …
Major Depressive Disorder (MDD) impacts millions globally, making it a significant public health challenge. Traditional treatments like Selective Serotonin Reuptake Inhibitors (SSRIs) don’t work for everyone, highlighting the need for innovative approaches. Recent clinical trials exploring the use of empagliflozin, a medication originally used to lower blood sugar in diabetes patients, have shown promising results …
Seroquel (Quetiapine) is an atypical antipsychotic drug that is used primarily for the treatment of schizophrenia and in some cases, bipolar disorder. It is also a relatively popular antidepressant augmentation strategy for individuals who don’t respond to monotherapeutic options. Off-label some doctors prescribe it at low doses for Tourette syndrome, insomnia and anxiety disorders, despite …
Risperdal (Risperidone) is an atypical antipsychotic drug that is primarily utilized to manage symptoms of schizophrenia. Additionally the drug is commonly prescribed for other conditions such as schizoaffective disorder, bipolar disorder, and for irritability associated with autism. It was initially approved by the FDA in 1994 and at the time was considered to be an …